- 专利标题: THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF
-
申请号: US18032724申请日: 2021-10-19
-
公开(公告)号: US20230391753A1公开(公告)日: 2023-12-07
- 发明人: Jae Hong Seo , Kee Dal Nam , Ji Young Kim , Yoon Jae Kim , Min Su Park , Yong Koo Kang
- 申请人: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
- 申请人地址: KR Seoul
- 专利权人: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
- 当前专利权人: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
- 当前专利权人地址: KR Seoul
- 优先权: KR 20200135175 2020.10.19 KR 20210138673 2021.10.18
- 国际申请: PCT/KR2021/014550 2021.10.19
- 进入国家日期: 2023-04-19
- 主分类号: C07D403/12
- IPC分类号: C07D403/12 ; C07D235/32 ; C07D409/12 ; C07D405/12 ; C07D401/12 ; A61P35/00
摘要:
The present invention relates to a thiobenzimidazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer, comprising the derivative as an active ingredient. The thiobenzimidazole derivative of the present invention exhibits cell toxicity by blocking the cell cycle of a cancer cell and inducing apoptosis when administered to an individual, as the derivative inhibits tubulin polymerization by being activated in the cancer cell, and, thus, the derivative can be used for prevention or treatment of cancer, desirably for prevention or treatment of triple-negative breast cancer.
信息查询